deCODE genetics Inc (DCGN)

HEALTH CARE: PHARMACEUTICALS
SIC: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

8 STURLUGATA REYJKAVIK, ICELAND

Develops drugs and DNA-based diagnostics based upon discoveries in the inherited causes of common diseases. The company has a computerized genealogy database covering the entire Icelandic population and genotypic and disease data from more than 100,000 volunteer participants.

View SEC Filings from DCGN instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding DCGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DCGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ARMSTRONG J NEAL

  • Director
0 2009-07-29 0

BEERY JAMES

  • Director
0 2009-07-29 0

COLLIER EARL M JR

  • Director
0 2009-07-29 0

MCGUIRE TERRANCE

  • Director
No longer subject to file 2008-12-01 0

SIGURDSSON JAKOB O S.V.P., CORPORATE DEVELOPMENT

  • Officer
379 2008-09-16 0

STATTIN NORINDER BIRGIT A

  • Director
0 2008-05-29 0

BUCK LINDA B

  • Director
0 2008-05-29 0

HARTMAN DANIEL L SR. VP PRODUCT DEVELOPMENT

  • Officer
0 2008-02-12 0

THIBAULT LANCE E CFO & TREASURER

  • Officer
0 2008-02-12 0

STEFANSSON KARI CHARIMAN, PRESIDENT & CEO

  • Officer
0 2008-02-12 0

NIELSEN AXEL CHIEF OPERATING OFFICER

  • Officer
0 2008-02-12 0

GURNEY MARK SR. VP DRUG DISCOVERY & DVLPMT

  • Officer
0 2008-02-12 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments